Want to test your knowledge about stem cells with this not-so-trivial trivia? Let’s see if you can do better than Giuliano and Nicola! (You probably can, especially better than Nicola…).
Thanks to Ulla-Kaisa Peteri for preparing the questions!
Category: biotech/medical – Page 2,289
Augmented Reality in a Contact Lens
Science fiction writers envisioned the technology decades ago, and startups have been working on developing an actual product for at least 10 years.
Today, Mojo Vision announced that it has done just that—put 14K pixels-per-inch microdisplays, wireless radios, image sensors, and motion sensors into contact lenses that fit comfortably in the eyes. The first generation of Mojo Lenses are being powered wirelessly, though future generations will have batteries on board. A small external pack, besides providing power, handles sensor data and sends information to the display. The company is calling the technology Invisible Computing, and company representatives say it will get people’s eyes off their phones and back onto the world around them.
The first application, says Steve Sinclair, senior vice president of product and marketing, will likely be for people with low vision—providing real-time edge detection and dropping crisp lines around objects. In a demonstration last week at CES 2020, I used a working prototype (albeit by squinting through the lens rather than putting it into my eyes), and the device highlighted shapes in bright green as I looked around a dimly lit room.
Exosome Therapy for Stroke Produces Full Recovery in Animal Model
Researchers reverse stroke damage in animal model using stem cell exosomes.
Expanding upon previous work that developed a treatment using a type of extracellular vesicles known as exosomes—small fluid-filled structures that are created by stem cells—investigators at the University of Georgia (UGA) present brain-imaging data for a new stroke treatment that supported full recovery in swine, modeled with the same pattern of neurodegeneration as seen in humans with severe stroke. Findings from this new study were published recently in Translational Stroke Research through an article titled “Neural Stem Cell Extracellular Vesicles Disrupt Midline Shift Predictive Outcomes in Porcine Ischemic Stroke Model.”
Amazingly, it’s been almost a quarter-century since the first drug was approved for stroke. Yet, what’s even more striking is that only a single drug remains approved today, so having a greater understanding of the molecular mechanisms that underlie stroke cases should lead to new therapies that could provide dramatic improvements in patient outcomes.
The researchers at UGA’s Regenerative Bioscience Center report the first observational evidence during a midline shift—when the brain is being pushed to one side—to suggest that a minimally invasive and nonoperative exosome treatment can now influence the repair and damage that follow a severe stroke.
LIfT BioSciences secures a further round of funding for its game-changing innate cell therapy for solid tumours
London, 15th January 2020 – Biotech LIfT BioSciences today announced a further major investment into the company in its mission to develop the first curative and affordable cell therapy for all solid tumours. The investors included Jonathan Milner, a leading biotech ‘super-angel’ investor and earlier stage investor in LIfT, Kizoo Technology Ventures, a leading early-stage investor in breakthrough technologies and Downing Ventures, a leading London-based investor.
AI-Designed ‘Living Robots’ Crawl, Heal Themselves
Biological organisms have certain useful attributes that synthetic robots do not, such as the abilities to heal, adapt to new situations, and reproduce. Yet molding biological tissues into robots or tools has been exceptionally difficult to do: Experimental techniques, such as altering a genome to make a microbe perform a specific task, are hard to control and not scalable.
Now, a team of scientists at the University of Vermont and Tufts University in Massachusetts has used a supercomputer to design novel lifeforms with specific functions, then built those organisms out of frog cells.
The new, AI-designed biological bots crawl around a petri dish and heal themselves. Surprisingly, the biobots also spontaneously self-organize and clear their dish of small trash pellets.
The mysterious, legendary giant squid’s genome is revealed
How did the monstrous giant squid—reaching school-bus size, with eyes as big as dinner plates and tentacles that can snatch prey 10 yards away—get so scarily big?
Today, important clues about the anatomy and evolution of the mysterious giant squid (Architeuthis dux) are revealed through publication of its full genome sequence by a University of Copenhagen-led team that includes scientist Caroline Albertin of the Marine Biological Laboratory (MBL), Woods Hole.
Giant squid are rarely sighted and have never been caught and kept alive, meaning their biology (even how they reproduce) is still largely a mystery. The genome sequence can provide important insight.
The History of the Pharma Cartel
The Supreme Court of the U.S. finds John Rockefeller and his Trust guilty of corruption, illegal business practices and racketeering. As a result of this decision, the entire Rockefeller Standard Oil-Trust, the world’s largest corporation of its time, was sentenced to be dismantled. But Rockefeller was already above the Supreme Court and did not care about this decision.
In order to disperse public and political pressure on him and other robber-barons, Rockefeller uses a trick called “philanthropy”, whereby the illegal gains from his robber-practices in the oil business are used to launch the Rockefeller Foundation. This tax haven was used to strategically take over the health care sector in the U.S…
The Rockefeller Foundation was the front organization for a new global business venture of Rockefeller and his accomplices. This new venture was called the pharmaceutical investment business. Donations from the Rockefeller Foundation went only to medical schools and hospitals. These institutions had become missionaries of a new breed of companies: the manufacturers of patented, synthetic drugs.
Figure 1: A CRISPR–Cas9 genetically engineered mouse model for MERS-CoV replication
A, C57BL/6J mice were genetically engineered using CRISPR–Cas9 genomic editing to encode 288L and 330R in mDPP4 on one chromosome (heterozygous, 288/330+/−) or on both chromosomes (homozygous, 288/330+/+). b, Northern blot of mDPP4 mRNA expression. c, Immunohistochemistry (IHC) of mDPP4 protein in the lungs, brain and kidneys of individual C57BL/6J wild-type (WT), 288/330+/− and 288/330+/+ mice. d, Viral titres for MERS-CoV at 3 days post-infection from C57BL/6J WT, 288/330+/− and 288/330+/+ (all n = 4) mice infected with 5 × 105 plaque-forming units (p.f.u.) of the indicated viruses. Bar graphs show means + s.d.